circRNA basic information
circBase ID: hsa_circ_0061179
Name: hsa_circ_ZBTB46
Synonym: circZBTB46
Host Gene: ZBTB46
Genomic location(hg19): chr20:62421173-62422143:-
Genomic location(hg38): chr20:62421173-6242214:.
Subcellular localization: cytoplasm
 
 
 
 
 
 
 
Disease basic information
MONDO ID:
0008170
MONDO name: ovarian cancer
Disease details: Ovarian cancer
Disease DO ID:
2394
Disease MeSH ID:
D010051
Disease NCIt ID:
C7431
Disease ICD11 ID:
685124533
Disease OMIM ID:
167000
Species: Human
Species details: Homo sapiens
Tissue specimen:

tumor tissues; normal ovarian tissues; human OC biospecimens

Cell lines:

SKOV3; CAOV3; HO8910; JHOS2; OVCAR3; A2780; IOSE80

In vivo animal model:

cell line-derived xenograft

circRNA-disease information
Expression pattern:
UP
Associated gene: TIMELESS, METTL3, YTHDC1, Ago2, p-ATR, p-CHK1, RAD51, gamma-H2AX
Associated microRNA: miR-143-3p
Biological function: Promotes OC cell proliferation, clone formation, migration and tumor growth; inhibits DNA damage and apoptosis.
Molecular mechanism: METTL3-mediated m6A modification promotes hsa_circ_0061179 circularization and stability, and YTHDC1 promotes its cytoplasmic transfer; cytoplasmic hsa_circ_0061179 acts as a ceRNA sponge for miR-143-3p to upregulate TIMELESS and activate ATR/CHK1 signaling, thereby inhibiting DNA damage and apoptosis.
Biological pathway or process:

proliferation (promotes); apoptosis (inhibits); migration (promotes); ceRNA regulation (other); m6A modification (other); other pathway/process (promotes)

Detected method:
Q
S
Validation methods:

Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; RT-qPCR; RNA-seq; Actinomycin D / DRB Stability Assay; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; MeRIP / MeRIP-seq; Transfection; CCK8; EdU Staining; Colony Formation Assay; Annexin V/PI Flow Cytometry; Transwell Assay; Wound Healing Assay; IF (Immunofluorescence); IHC (Immunohistochemistry); Western Blot; In Vivo Animal Model; Survival Analysis; Bioinformatics Analysis

Clinical significance:

High hsa_circ_0061179 expression was associated with inferior survival, advanced FIGO stage, and positive lymph node metastasis in OC patients; the hsa_circ_0061179/miR-143-3p/TIMELESS axis suggests therapeutic target potential.

Description:

hsa_circ_0061179/circZBTB46 is up-regulated in ovarian cancer and high expression is associated with poorer survival and more advanced clinicopathological features. Mechanistically, METTL3-mediated m6A modification enhances hsa_circ_0061179 expression and stability, YTHDC1 promotes its cytoplasmic export, and cytoplasmic hsa_circ_0061179 sponges miR-143-3p to increase TIMELESS and activate ATR/CHK1-related DNA damage repair signaling, thereby promoting proliferation, migration and tumor growth while inhibiting apoptosis and DNA damage.

Confidence score:

0.8933

Other information
Title:

M6A-mediated hsa_circ_0061179 inhibits DNA damage in ovarian cancer cells via miR-143-3p/TIMELESS.

Journal: Molecular carcinogenesis
Published: 2024
PubMed ID: 38751015
Study type:

combined biological and clinical study

Data availability: The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.
Code availability: -